← Patent-cliff monitor small molecule XENLETA LEFAMULIN ACETATE
Loss of exclusivity June 2036 latest FDA-listed patent expiry
Company HONG KONG KING FRIEND INDUSTRIAL CO LTD
Drug detail Brand name XENLETA Active ingredient LEFAMULIN ACETATE Strength EQ 150MG BASE/15ML (EQ 10MG BASE/ML) Dosage form SOLUTION Route INTRAVENOUS Modality Small molecule FDA approval August 2019 Marketing status RX
Listed patents Patent Expires Type 12121582 June 2036 product 8071643 March 2033 substance, product 8153689 March 2028 substance, product
Regulatory exclusivity Code Expires GAIN August 2029 NCE August 2024
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.